Sun Pharmaceutical Industries has received a blow from the US Food and Drug Administration after the US agency imposed an import alert on its Halol, Gujarat manufacturing site in India.
Sun Grapples With Impact Of Halol FDA Import Alert
US Supplies From Non-Compliant Plant Account For 3% Of Annual Sales
Sun Pharma’s Halol facility has been placed under an import alert by the FDA following an inspection earlier this year that uncovered GMP deficiencies.
More from Manufacturing
More from Business
• By
Meitheal Pharmaceuticals said that its generic version of the GLP-1 agonist Victoza would be one of 22 planned launches during 2025, as the firm continues to build out its portfolio with the aid of its parent, Hong Kong King-Friend Industrial.
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.